Haemonetics has patented a method for closing blood vessel puncture sites using a closure device that accelerates the hemostatic process. The method involves deploying an expansible member, retracting the device, deploying a tensioning coil, and exposing a chemical/biological agent release region to promote clotting. GlobalData’s report on Haemonetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Haemonetics Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Haemonetics, Glucose monitoring wearbles was a key innovation area identified from patents. Haemonetics's grant share as of January 2024 was 53%. Grant share is based on the ratio of number of grants to total number of patents.

Vascular closure device using natural and chemical/biological agents

Source: United States Patent and Trademark Office (USPTO). Credit: Haemonetics Corp

A recently granted patent (Publication Number: US11871916B2) discloses a method for closing a blood vessel puncture site using a closure device equipped with an expansible member and a tensioning coil. The method involves deploying the expansible member within the blood vessel, retracting the closure device to seat the expansible member against the puncture site, and using the tensioning coil to gauge and apply appropriate tension to prevent excessive force during the closure process. Additionally, the tensioning coil provides compliance to patient movement, preventing the closure device from being dislodged.

Furthermore, the method includes positioning a chemical and/or biological agent release region proximal to the expansible member, coated on the tensioning coil, at a predetermined distance from the puncture site. The tensioning coil not only applies tension to the expansible member but also elongates based on the applied tension, with a specified range of tension from about 0.5 ounce to 30 ounces. After achieving hemostasis in the tissue tract, the tensioning coil is released, collapsing the expansible member, and allowing for the retraction of the closure device, including both the expansible member and the tensioning coil, from the tissue tract.

To know more about GlobalData’s detailed insights on Haemonetics, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.